



Daré Bioscience Announces Participation in Two Upcoming Virtual Conferences

September 8, 2020

SAN DIEGO, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that Sabrina Martucci Johnson, Daré's President and CEO, will participate in two upcoming virtual conferences:

Women's Health Innovation Summit 2020

Ms. Johnson will participate in two panel discussions:

Health Decisions' Expert Panel: A Women-centric Approach to Clinical Research

Date: Monday, September 14, 2020

Time: 10:20 AM EDT

CEO Leadership Panel

Date: Tuesday, September 15, 2020

Time: 9:25 AM EDT

There will be a brief Live Q&A session following the *CEO Leadership Panel*. Both panel discussions will be available on-demand during the conference for all registered virtual event attendees.

Event registration for the Women's Health Innovation Summit 2020 is available at <https://www.kisacoresearch.com/events/womens-health-innovation-summit#register>.

H.C. Wainwright 22nd Annual Global Investment Conference

Ms. Johnson will present a Company update on September 15, 2020 at 4:00 PM EDT.

A live webcast of the presentation will be available via the Investors section of the Company's website at <https://ir.darebioscience.com/events-presentations>. An archive of the presentation will be available for replay through September 29, 2020.

About Daré Bioscience

Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women's health. The company's mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health, and fertility.

Daré's clinical-stage product portfolio includes potential first-in-category candidates in clinical development: Ovaprene®, a hormone-free, monthly contraceptive intravaginal ring whose U.S. commercial rights are under a license agreement with Bayer; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil to treat female sexual arousal disorder utilizing the active ingredient in Viagra®; DARE-BV1, a unique hydrogel formulation of clindamycin phosphate 2% to treat bacterial vaginosis via a single application; and DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for hormone replacement therapy following menopause. To learn more about Daré's full portfolio of women's health product candidates, and mission to deliver differentiated therapies for women, please visit www.darebioscience.com.

Daré may announce material information about its finances, product candidates, clinical trials and other matters using its investor relations website (<http://ir.darebioscience.com>), SEC filings, press releases, public conference calls and webcasts. Daré will use these channels to distribute material information about the company, and may also use social media to communicate important information about the company, its finances, product candidates, clinical trials and other matters. The information Daré posts on its investor relations website or through social media channels may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts on its investor relations website (<https://darebioscience.qcs-web.com/>) and to follow these Twitter accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted on the investor relations page of Daré's website mentioned above.

Contacts:

Investors on behalf of Daré Bioscience, Inc.:

Lee Roth

Burns McClellan

lroth@burnsmc.com

212.213.0006

Source: Daré Bioscience, Inc.



Source: Daré Bioscience, Inc.